20220159 Avacopan for ANCA-associated Vasculitis

Internal Medicine Immunology Autoimmune Adult Subjects

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Preventing Injured Knees from osteoArthritis: Severity Outcomes (PIKASO)

Endocrinology Orthopedics Immunology Diabetes Arthritis Adult Subjects

This study is being done to find out if metformin is effective at reducing pain by delaying the onset of post-traumatic osteoarthritis (PTOA) after anterior cruciate ligament (ACL) reconstruction. This research study will compare metformin to placebo. The placebo tablet looks exactly like metformin, but contains no metformin. Placebos are used in research studies to see if the results are due to the study drug or due to other reasons. Metformin is approved by the U.S. Food and Drug Administration (FDA) to treat type II diabetes. Notably, it also has anti-inflammatory effects, suggesting it could benefit people who have an ACL injury and are undergoing ACL reconstruction.

MPCT-021N, IMPT-514 for SLN and SLE

Internal Medicine Immunology Nephrology Autoimmune Kidney Disease Adult Subjects

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-514, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with active, refractory lupus nephritis and systemic lupus erythematosus. IMPT-514 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide. Individual participants will remain in the active post-treatment period for approximately 1 year. Participants will continue in long-term follow-up for 15 years from treatment.

Celldex CDX0159-08 EoE

Internal Medicine Immunology Gastroenterology Esophagitis Digestive Disease Adult Subjects

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.

Celgene CC-93538-DDI-001 Phase 1 EoE

Internal Medicine Immunology Gastroenterology Esophagitis Digestive Disease Adult Subjects

The purpose of this study to evaluate the potential for disease-mediated drug-drug interactions between cendakimab and selected substrates of metabolic enzymes in eosinophilic esophagitis participants.

A Randomized, Multi-Center, Double-Blind, Parallel Study to Examine the Effect of Lipogems Processed Microfragmented Adipose Tissue in Comparison to Corticosteroid for the Treatment of Knee Osteoarthritis

Orthopedics Immunology Arthritis Adult Subjects

The goal of this clinical trial is to examine the effect of a single autologous, intra-articular injection of MFat versus corticosteroid injection for the treatment of pain and function associated with K/L grade 2/3 knee Osteoarthritis. Participants will receive an injection of MFat or a corticosteroid.

AIS-D04, ALPN-303, Autoimmune Cytopenias

Internal Medicine Immunology Autoimmune Adult Subjects

The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.

AstraZeneca D5244C00001 Crossing EoE

Internal Medicine Immunology Gastroenterology Esophagitis Digestive Disease Adult Subjects

A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).

Subscribe to Immunology